Gene Rv1979c
in Mycobacterium tuberculosis H37Rv
General annotation
| Type | CDS |
| Function | Unknown; possibly involved in transport of amino acid across the membrane. |
| Product | Possible conserved permease |
| Comments | Rv1979c, (MTCY39.40-MTV051.17c), len: 481 aa. Possible permease, APC family possibly involved in transport of amino acid, showing some similarity to other permeases. Also similar to MTCY39.19 from Mycobacterium tuberculosis (28.2% identity in 277 aa overlap). Contains PS00599 Aminotransferases class-II pyridoxal-phosphate attachment site. Nucleotide position 2221796 in the genome sequence has been corrected, C:T resulting in V457I. |
| Functional category | Cell wall and cell processes |
| Mutant | Non-essential gene for in vitro growth of H37Rv in a MtbYM rich medium, by Himar1 transposon mutagenesis (see Minato et al. 2019). Disruption of this gene provides a growth advantage for in vitro growth of H37Rv, by analysis of saturated Himar1 transposon libraries (see DeJesus et al. 2017). Non essential gene by Himar1 transposon mutagenesis in CDC1551 strain (see Lamichhane et al., 2003). Non-essential gene for in vitro growth of H37Rv, by Himar1 transposon mutagenesis (See Griffin et al., 2011). Check for mutants available at TARGET website |
Coordinates
| Type | Start | End | Orientation |
|---|---|---|---|
| CDS | 2221719 | 2223164 | - |
Genomic sequence
Feature type
Upstream flanking region (bp)
Downstream flanking region (bp)
Update
Protein sequence
>Mycobacterium tuberculosis H37Rv|Rv1979c|Rv1979c
VVGPRTRGYAIHKLGFCSVVMLGINSIIGAGIFLTPGEVIGLAGPFAPMAYVLAGIFAGVVAIVFATAARYVRTNGASYAYTTAAFGRRIGIYVGVTHAITASIAWGVLASFFVSTLLRVAFPDKAWADAEQLFSVKTLTFLGFIGVLLAINLFGNRAIKWANGTSTVGKAFALSAFIVGGLWIITTQHVNNYATAWSAYSATPYSLLGVAEIGKGTFSSMALATIVALYAFTGFESIANAAEEMDAPDRNLPRAIPIAIFSVGAIYLLTLTVAMLLGSNKIAASDDTVKLAAAIGNATFRTIIVVGALISMFGINVAASFGAPRLWTALADSGVLPTRLSRKNQYDVPMVSFAITASLALAFPLALRFDNLHLTGLAVIARFVQFIIVPIALIALARSQAVEHAAVRRNAFTDKVLPLVAIVVSVGLAVSYDYRCIFLVRGGPNYFSIALIVITFIVVPAMAYLHYYRIIRRVGDRPSTR
Bibliography
- Mattow J, Jungblut PR, Schaible UE, Mollenkopf HJ, Lamer S, Zimny-Arndt U, Hagens K, Muller EC and Kaufmann SH [2001]. Identification of proteins from Mycobacterium tuberculosis missing in attenuated Mycobacterium bovis BCG strains. Proteomics
- Cockle PJ et al. [2002]. Identification of novel Mycobacterium tuberculosis antigens with potential as diagnostic reagents or subunit vaccine candidates by comparative genomics. Biochemistry Immunology
- Niemann S, Koser CU, Gagneux S, Plinke C, Homolka S, Bignell H, Carter RJ, Cheetham RK, Cox A, Gormley NA, Kokko-Gonzales P, Murray LJ, Rigatti R, Smith VP, Arends FP, Cox HS, Smith G and Archer JA [2009]. Genomic diversity among drug sensitive and multidrug resistant isolates of Mycobacterium tuberculosis with identical DNA fingerprints. Sequence
- Ioerger TR et al. [2010]. Variation among genome sequences of H37Rv strains of Mycobacterium tuberculosis from multiple laboratories. Sequence
- Griffin JE et al. [2011]. High-resolution phenotypic profiling defines genes essential for mycobacterial growth and cholesterol catabolism. Mutant
- Kozak RA et al. [2011]. Region of difference 2 contributes to virulence of Mycobacterium tuberculosis. Mutant Immunology
- Kozak R et al. [2011]. Divergence of immunologic and protective responses of different BCG strains in a murine model. Immunology
- Zhang S et al. [2015]. Identification of novel mutations associated with clofazimine resistance in Mycobacterium tuberculosis. Regulation Clinical
- DeJesus MA et al. [2017]. Comprehensive Essentiality Analysis of the Mycobacterium tuberculosis Genome via Saturating Transposon Mutagenesis. Mutant
- Xu J et al. [2017]. Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis. Clinical
- Zimenkov DV et al. [2017]. Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region. Clinical
- Ismail N et al. [2018]. In vitro approaches for generation of Mycobacterium tuberculosis mutants resistant to bedaquiline, clofazimine or linezolid and identification of associated genetic variants. Clinical
- Ismail N et al. [2018]. Collated data of mutation frequencies and associated genetic variants of bedaquiline, clofazimine and linezolid resistance in Mycobacterium tuberculosis. Clinical
- Minato Y et al. [2019]. Genomewide Assessment of Mycobacterium tuberculosis Conditionally Essential Metabolic Pathways. Mutant
- Otchere ID et al. [2019]. Molecular epidemiology and whole genome sequencing analysis of clinical Mycobacterium bovis from Ghana. Clinical
- Merker M et al. [2020]. Phylogenetically informative mutations in genes implicated in antibiotic resistance in Mycobacterium tuberculosis complex. Secondary
- Kadura S et al. [2020]. Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid. Review Clinical
- Nimmo C et al. [2020]. Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in southern Africa: a phenotypic and phylogenetic analysis. Clinical
- Ismail N et al. [2021]. Genetic variants and their association with phenotypic resistance to bedaquiline in Mycobacterium tuberculosis: a systematic review and individual isolate data analysis. Review Clinical
- Saeed DK et al. [2022]. Variants associated with Bedaquiline (BDQ) resistance identified in Rv0678 and efflux pump genes in Mycobacterium tuberculosis isolates from BDQ naïve TB patients in Pakistan. Clinical
- Park S et al. [2022]. Investigation of Clofazimine Resistance and Genetic Mutations in Drug-Resistant Mycobacterium tuberculosis Isolates. Clinical
- Trisakul K et al. [2022]. High clustering rate and genotypic drug-susceptibility screening for the newly recommended anti-tuberculosis drugs among global extensively drug-resistant Mycobacterium tuberculosis isolates. Clinical
- Shang Y et al. [2023]. Bedaquiline resistance pattern in clofazimine-resistant clinical isolates of tuberculosis patients. Clinical
- An Q et al. [2023]. Evaluation of genetic mutations associated with phenotypic resistance to fluoroquinolones, bedaquiline, and linezolid in clinical Mycobacterium tuberculosis: A systematic review and meta-analysis. Review Clinical
- Perumal R et al. [2023]. Mycobacterium tuberculosis Intra-Host Evolution Among Drug-Resistant Tuberculosis Patients Failing Treatment. Clinical
- Anlay DZ et al. [2023]. A Bayesian approach to estimate the probability of resistance to bedaquiline in the presence of a genomic variant. Secondary
- Tong E et al. [2023]. Bedaquiline Resistance and Molecular Characterization of Rifampicin-Resistant Mycobacterium Tuberculosis Isolates in Zhejiang, China. Clinical
- Derendinger B et al. [2023]. Bedaquiline resistance in patients with drug-resistant tuberculosis in Cape Town, South Africa: a retrospective longitudinal cohort study. Clinical
- Islam MM et al. [2023]. Molecular mechanisms of resistance and treatment efficacy of clofazimine and bedaquiline against Mycobacterium tuberculosis. Review Biochemistry Clinical
- Balgouthi K et al. [2024]. Mutations in Rv0678, Rv2535c, and Rv1979c Confer Resistance to Bedaquiline in Clinical Isolates of Mycobacterium Tuberculosis. Clinical
- Chen S et al. [2025]. In vitro monitoring of drug resistance emergence during stepwise induction of bedaquiline and clofazimine, alone and in combination: a phenotypic and genotypic analysis. Clinical
- Balgouthi K et al. [2025]. Examination of Genetic Mutations of Clofazimine Resistance in Drug-Resistant Mycobacterium TB Isolates. Clinical
- Malope P et al. [2026]. Bedaquiline resistance-associated genetic mutations and minimum inhibitory concentrations in drug-resistant tuberculosis clinical isolates from Limpopo province, South Africa. Clinical
- Victor AS et al. [2026]. Phenotypic drug susceptibility testing and genotypic characterization of Bedaquiline resistance in drug resistant Mycobacteriumtuberculosis. Clinical
- Luo M et al. [2026]. Comparative in vitro antimicrobial susceptibility profiles of clofazimine and pyrifazimine against clinical isolates of Mycobacterium tuberculosis in southwest China. Mutant Biochemistry Clinical
- Massou F et al. [2026]. No phenotypic resistance observed for most group-3 and -4 variants in Mycobacterium tuberculosis genes related to bedaquiline, clofazimine, delamanid, and pretomanid in a Central and West African context. Clinical
- Muhammad N et al. [2026]. Mutational profiling of ESX/type VII secretion system-associated genes in drug-resistant Mycobacterium tuberculosis from Khyber Pakhtunkhwa, Pakistan. Clinical